Angiogenesis as targeted breast cancer therapy

Daniel F. Hayes, Kathy Miller, George Sledge

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Neo-angiogenesis appears to be a critical feature of tumor growth, migration, and metastasis. Therefore, inhibition of angiogenesis is an appealing strategy for treatment of cancer. Since angiogenesis is the result of several mechanistic processes, controlled by numerable pro- and anti-angiogenic factors and their receptors, multiple possibilities to prevent or reverse tumor-induced neo-vascularization have been proposed. Of these, currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Bevacizumab has been shown to be active in several malignancies, in particular colo-rectal cancer. Although early studies of bevacizumab in far-advanced metastatic breast cancer were disappointing, the results of a recently reported clinical trial by the Eastern Oncology Group comparing first line paclitaxel with or without bevacizumab has demonstrated statistically significant improvements in response rates and time progression. Ongoing studies are now investigating the benefits of bevacizumab with other chemotherapeutic and biologic agents in early metastatic disease as well as in the adjuvant setting. Other anti-angiogenic agents remain in early clinical trials. Small molecular inhibitors of VEGF receptor tyrosine kinase activity, such as sunitinib, appear promising. Nearly 40 years after it was first proposed, inhibition of angiogenesis appears to be gaining a role in medical oncology.

Original languageEnglish
Pages (from-to)17-19
Number of pages3
JournalBreast
Volume16
Issue number2 SUPPL.
DOIs
StatePublished - 2007

Fingerprint

Breast Neoplasms
Angiogenesis Inducing Agents
Neoplasms
Clinical Trials
Therapeutics
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor Receptor
Medical Oncology
Biological Factors
Rectal Neoplasms
Paclitaxel
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Bevacizumab
Neoplasm Metastasis
Growth

Keywords

  • Angiogenesis
  • Bevacizumab
  • Breast cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Angiogenesis as targeted breast cancer therapy. / Hayes, Daniel F.; Miller, Kathy; Sledge, George.

In: Breast, Vol. 16, No. 2 SUPPL., 2007, p. 17-19.

Research output: Contribution to journalArticle

Hayes, Daniel F. ; Miller, Kathy ; Sledge, George. / Angiogenesis as targeted breast cancer therapy. In: Breast. 2007 ; Vol. 16, No. 2 SUPPL. pp. 17-19.
@article{f5881894ade64b3faf94fa3a4ffeaba8,
title = "Angiogenesis as targeted breast cancer therapy",
abstract = "Neo-angiogenesis appears to be a critical feature of tumor growth, migration, and metastasis. Therefore, inhibition of angiogenesis is an appealing strategy for treatment of cancer. Since angiogenesis is the result of several mechanistic processes, controlled by numerable pro- and anti-angiogenic factors and their receptors, multiple possibilities to prevent or reverse tumor-induced neo-vascularization have been proposed. Of these, currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Bevacizumab has been shown to be active in several malignancies, in particular colo-rectal cancer. Although early studies of bevacizumab in far-advanced metastatic breast cancer were disappointing, the results of a recently reported clinical trial by the Eastern Oncology Group comparing first line paclitaxel with or without bevacizumab has demonstrated statistically significant improvements in response rates and time progression. Ongoing studies are now investigating the benefits of bevacizumab with other chemotherapeutic and biologic agents in early metastatic disease as well as in the adjuvant setting. Other anti-angiogenic agents remain in early clinical trials. Small molecular inhibitors of VEGF receptor tyrosine kinase activity, such as sunitinib, appear promising. Nearly 40 years after it was first proposed, inhibition of angiogenesis appears to be gaining a role in medical oncology.",
keywords = "Angiogenesis, Bevacizumab, Breast cancer",
author = "Hayes, {Daniel F.} and Kathy Miller and George Sledge",
year = "2007",
doi = "10.1016/j.breast.2007.07.003",
language = "English",
volume = "16",
pages = "17--19",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Angiogenesis as targeted breast cancer therapy

AU - Hayes, Daniel F.

AU - Miller, Kathy

AU - Sledge, George

PY - 2007

Y1 - 2007

N2 - Neo-angiogenesis appears to be a critical feature of tumor growth, migration, and metastasis. Therefore, inhibition of angiogenesis is an appealing strategy for treatment of cancer. Since angiogenesis is the result of several mechanistic processes, controlled by numerable pro- and anti-angiogenic factors and their receptors, multiple possibilities to prevent or reverse tumor-induced neo-vascularization have been proposed. Of these, currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Bevacizumab has been shown to be active in several malignancies, in particular colo-rectal cancer. Although early studies of bevacizumab in far-advanced metastatic breast cancer were disappointing, the results of a recently reported clinical trial by the Eastern Oncology Group comparing first line paclitaxel with or without bevacizumab has demonstrated statistically significant improvements in response rates and time progression. Ongoing studies are now investigating the benefits of bevacizumab with other chemotherapeutic and biologic agents in early metastatic disease as well as in the adjuvant setting. Other anti-angiogenic agents remain in early clinical trials. Small molecular inhibitors of VEGF receptor tyrosine kinase activity, such as sunitinib, appear promising. Nearly 40 years after it was first proposed, inhibition of angiogenesis appears to be gaining a role in medical oncology.

AB - Neo-angiogenesis appears to be a critical feature of tumor growth, migration, and metastasis. Therefore, inhibition of angiogenesis is an appealing strategy for treatment of cancer. Since angiogenesis is the result of several mechanistic processes, controlled by numerable pro- and anti-angiogenic factors and their receptors, multiple possibilities to prevent or reverse tumor-induced neo-vascularization have been proposed. Of these, currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Bevacizumab has been shown to be active in several malignancies, in particular colo-rectal cancer. Although early studies of bevacizumab in far-advanced metastatic breast cancer were disappointing, the results of a recently reported clinical trial by the Eastern Oncology Group comparing first line paclitaxel with or without bevacizumab has demonstrated statistically significant improvements in response rates and time progression. Ongoing studies are now investigating the benefits of bevacizumab with other chemotherapeutic and biologic agents in early metastatic disease as well as in the adjuvant setting. Other anti-angiogenic agents remain in early clinical trials. Small molecular inhibitors of VEGF receptor tyrosine kinase activity, such as sunitinib, appear promising. Nearly 40 years after it was first proposed, inhibition of angiogenesis appears to be gaining a role in medical oncology.

KW - Angiogenesis

KW - Bevacizumab

KW - Breast cancer

UR - http://www.scopus.com/inward/record.url?scp=35648973650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35648973650&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2007.07.003

DO - 10.1016/j.breast.2007.07.003

M3 - Article

VL - 16

SP - 17

EP - 19

JO - Breast

JF - Breast

SN - 0960-9776

IS - 2 SUPPL.

ER -